ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • canakinumab and Biologics
  • Canakinumab and caregivers
  • canakinumab and corticosteroids
  • canakinumab and familial Mediterranean fever
  • canakinumab and fever
  • canakinumab and interleukins (IL)
  • canakinumab and juvenile arthritis
  • canakinumab and juvenile idiopathic arthritis (JIA)
  • canakinumab and monoclonal antibodies
  • Canakinumab and safety
  • canakinumab and tocilizumab
  • canakinumab and treatment
  • Cancer
  • cancer and cancer treatments
  • cancer and clinical practice
  • Cancer and cutaneous lupus erythematosus
  • cancer and histopathologic
  • cancer and human papillomavirus (HPV)
  • cancer and immunosuppressants
  • Cancer and inflammatory arthritis
  • cancer and Janus kinase (JAK)
  • cancer and lymphopenia
  • cancer and malignancy
  • Cancer and myositis
  • cancer and nonsteroidal antiinflammatory drugs (NSAIDs)
  • cancer and Oncology
  • cancer and patient preferences
  • Cancer and polymyositis/dermatomyositis (PM/DM)
  • Cancer and psoriatic arthritis
  • cancer and registry
  • cancer and Reproductive Health
  • cancer and rheumatoid arthritis (RA)
  • cancer and scleroderma
  • cancer and systemic lupus erythematosus (SLE)
  • Cancer treatments
  • cancer treatments and immune response
  • cancer treatments and Immunotherapy
  • cancer treatments and inflammatory arthritis
  • cancer treatments and medical education
  • cancer treatments and morbidity and mortality
  • cancer treatments and myositis
  • Cancer treatments and osteoporosis
  • cancer treatments and rheumatoid arthritis (RA)
  • cancer treatments and rheumatologic disease
  • Cancer treatments and rituximab
  • cancer treatments and sarcoidosis
  • cancer treatments and systemic sclerosis
  • cannabidiol
  • cannabinoid
  • cannabinoid and clinical trials
  • cannabinoid and patient-reported outcome measures
  • Capillaroscopy
  • capillaroscopy and chemokines
  • capillaroscopy and nailfold capillaroscopy
  • capillaroscopy and scleroderma
  • Capillaroscopy and systemic lupus erythematosus (SLE)
  • capillaroscopy and systemic sclerosis
  • capillary microscopy
  • capillary microscopy and autoantibodies
  • capillary microscopy and connective tissue diseases
  • CAPS
  • carboxypeptidase B and rheumatoid arthritis (RA)
  • card9
  • Cardiac amyloidosis (CA)
  • cardiac and anti-TNF therapy
  • Cardiac fibrosis
  • cardiac MRI
  • Cardiac Sarcoidosis
  • cardiac structure and follow up
  • cardiotoxicity and BNP
  • Cardiovascular
  • Cardiovascular and rheumatoid arthritis
  • Cardiovascular disease
  • cardiovascular disease and administrative databases
  • cardiovascular disease and antiphospholipid antibodies
  • cardiovascular disease and assessment
  • cardiovascular disease and big data
  • cardiovascular disease and biomarkers
  • cardiovascular disease and cholesterol
  • cardiovascular disease and Co-morbidities
  • cardiovascular disease and comorbidity
  • cardiovascular disease and computed tomography (CT)
  • cardiovascular disease and CT scan
  • Cardiovascular disease and cutaneous lupus erythematosus
  • cardiovascular disease and death
  • cardiovascular disease and depression
  • cardiovascular disease and diabetes
  • Cardiovascular disease and diffuse idiopathic skeletal hyperostosis (DISH)
  • cardiovascular disease and Disease Activity
  • cardiovascular disease and endothelial cells
  • cardiovascular disease and epidemiologic methods
  • cardiovascular disease and exercise
  • cardiovascular disease and extraarticular manifestations
  • cardiovascular disease and eye
  • cardiovascular disease and fibrosis
  • cardiovascular disease and genetic disorders
  • cardiovascular disease and genetics
  • Cardiovascular disease and giant cell arteritis
  • Cardiovascular disease and glucocorticoids
  • cardiovascular disease and gout
  • cardiovascular disease and high risk
  • Cardiovascular disease and hydroxychloroquine
  • cardiovascular disease and hyperuricemia
  • cardiovascular disease and immunoglobulin (IG)
  • cardiovascular disease and inflammation
  • cardiovascular disease and inflammatory arthritis
  • Cardiovascular disease and juvenile arthritis
  • cardiovascular disease and juvenile dermatomyositis
  • Cardiovascular disease and juvenile idiopathic arthritis (JIA)
  • cardiovascular disease and juvenile SLE
  • cardiovascular disease and large vessel vasculitis
  • cardiovascular disease and lipids
  • cardiovascular disease and longitudinal studies
  • cardiovascular disease and meta-analysis
  • cardiovascular disease and metabolism
  • cardiovascular disease and methotrexate (MTX)
  • cardiovascular disease and morbidity and mortality
  • cardiovascular disease and mycophenolate mofetil
  • cardiovascular disease and myocardial infarction
  • Cardiovascular disease and myositis
  • cardiovascular disease and nonsteroidal antiinflammatory drugs (NSAIDs)
  • Cardiovascular disease and nutrition
  • cardiovascular disease and obesity
  • Cardiovascular disease and osteoporosis
  • cardiovascular disease and outcomes
  • cardiovascular disease and pediatric rheumatology
  • cardiovascular disease and phenotypes
  • cardiovascular disease and physical activity
  • cardiovascular disease and platelets
  • Cardiovascular disease and polymyalgia rheumatica
  • cardiovascular disease and prevention
  • cardiovascular disease and primary care
  • cardiovascular disease and prognostic factors
  • Cardiovascular disease and psoriatic arthritis
  • cardiovascular disease and race/ethnicity
  • cardiovascular disease and radiography
  • cardiovascular disease and reactive arthritis
  • Cardiovascular disease and rheumatic disease
  • cardiovascular disease and rheumatoid arthritis
  • Cardiovascular disease and rheumatoid arthritis (RA)
  • cardiovascular disease and risk
  • cardiovascular disease and risk assessment
  • cardiovascular disease and rituximab
  • cardiovascular disease and sex hormones
  • cardiovascular disease and statins
  • cardiovascular disease and systemic lupus erythematosus (SLE)
  • Cardiovascular disease and systemic sclerosis
  • cardiovascular disease and systemic vasculitides
  • cardiovascular disease and thrombosis
  • Cardiovascular disease and tocilizumab
  • cardiovascular disease and tofacitinib
  • cardiovascular disease and ultrasonography
  • cardiovascular disease and uric acid
  • cardiovascular disease and weight loss
  • Cardiovascular Diseases
  • cardiovascular risk and activity score
  • Cardiovascular risk assessment
  • Career
  • career and fellowship programs
  • Career and mentor
  • caregivers
  • caregivers and quality of life
  • caregivers and rheumatic disease
  • Carotid Artery Disease
  • carotid plaque and cardiovascular disease
  • Carpal tunnel syndrome
  • Carpal tunnel syndrome and corticosteroids
  • carpal tunnel syndrome and sonography
  • CARRA Registry
  • cartilage
  • cartilage and chondrocytes
  • cartilage and effusion
  • cartilage and exercise
  • cartilage and imaging techniques
  • cartilage and magnetic resonance imaging (MRI)
  • cartilage and methotrexate (MTX)
  • cartilage and mouse model
  • cartilage and osteoarthritis
  • cartilage and pain
  • cartilage and race/ethnicity
  • cartilage and rheumatoid arthritis
  • cartilage and rheumatoid arthritis (RA)
  • Cartilage and stem cells
  • cartilage and synovitis
  • cartilage and transforming growth factor
  • Cartilage Degradation
  • Cartilage Matrix
  • Cartilage Mechano biology
  • Cartilage Repair
  • Case Report
  • Case-based
  • Castleman's disease
  • Castleman's disease and IgG4 Related Disease
  • catastrophic antiphospholipid syndrome and clinical practice guidelines
  • Catecholamines
  • catecholamines and cytokines
  • catecholamines and regulatory cells
  • Cathepsin
  • cathepsin g
  • cathepsin k inhibitor
  • First |
  • « Previous Page
  • 6
  • 7
  • 8
  • 9
  • 10
  • [11]
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology